Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 05, 2021 16:15 ET | Source: ProQR Therapeutics N.V.

ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares

LEIDEN, Netherlands and CAMBRIDGE, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated to changing lives through the creation of transformative...
April 02, 2021 16:15 ET | Source: ProQR Therapeutics N.V.

ProQR Announces Virtual Presentation at American Association for Pediatric Ophthalmology and Strabismus (AAPOS) 2021

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 02, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
March 30, 2021 22:25 ET | Source: ProQR Therapeutics N.V.

ProQR Prices $90 Million Underwritten Public Offering of Ordinary Shares

LEIDEN, Netherlands and CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated to changing lives through the creation of transformative RNA...
March 30, 2021 16:05 ET | Source: ProQR Therapeutics N.V.

ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

LEIDEN, Netherlands & CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated to changing lives through the creation of transformative...
March 24, 2021 07:00 ET | Source: ProQR Therapeutics N.V.

ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials

QR-421a demonstrated a concordant benefit in multiple measures of vision, including best corrected visual activity (BCVA), static perimetry, and retinal imaging (OCT)QR-421a observed to be well...
March 17, 2021 07:00 ET | Source: ProQR Therapeutics N.V.

ProQR to Present Results from Phase 1/2 Trial of QR-421a for Usher Syndrome

LEIDEN, Netherlands & CAMBRIDGE, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
March 02, 2021 16:30 ET | Source: ProQR Therapeutics N.V.

ProQR Announces Webcast of Presentation at Upcoming HC Wainwright Global Life Sciences Conference

LEIDEN, Netherlands & CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
February 25, 2021 07:00 ET | Source: ProQR Therapeutics N.V.

ProQR Announces Fourth Quarter and Full Year 2020 Operating and Financial Results

Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022; Brighten pediatric trial of sepofarsen to begin in 2021; additional data from...
February 16, 2021 16:30 ET | Source: ProQR Therapeutics N.V.

ProQR Announces Expert Perspectives Call on Disease Education and Endpoints in Usher Syndrome

LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
January 07, 2021 07:00 ET | Source: ProQR Therapeutics N.V.

ProQR Completes Enrollment of its Pivotal Trial of Sepofarsen for the Treatment of LCA10

Top-line results expected H1 2022Sepofarsen is a potential first-in-class RNA therapy for the treatment of LCA10, a rare inherited retinal disorder that leads to blindness LEIDEN, Netherlands...